Company intelligence / Profile preview

SNLD

Ibusuki City, Kagoshima Prefecture, Japantni.org ↗

Ownership: Private
Development stage: Other

Overview

SNLD is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL) focused on proprietary nasal drug delivery technologies. Its platform enables intranasal administration of therapeutics, as demonstrated by its use in Satsuma Pharmaceuticals’ Atzumi™ (dihydroergotamine) nasal powder, which received FDA approval for acute migraine treatment in 2025.

Therapeutic areas: Neurology
Modalities: Small molecule (via nasal powder delivery)Potentially others via nasal drug delivery platform (not specified)
Industry: Biotech

Drug pipeline

1 asset

TRN501

Partnerships

Satsuma Pharmaceuticals is a key partner/licensee utilizing the SNLD/SNBL nasal drug delivery platform for their approved product Atzumi™

Beyond the preview

Go deeper on SNLD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNLD.

Explore the full profile